A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

PURPOSE: An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥70 yr) with untreated acute myeloid leukemia (AML). EXPERIMENTAL DESIGN: Phase I evaluated the safety of obatoclax infused for 3 hours on...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Schimmer, Aaron D., Raza, Azra, Carter, Thomas H., Claxton, David, Erba, Harry, DeAngelo, Daniel J., Tallman, Martin S., Goard, Carolyn, Borthakur, Gautam
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186779/
https://ncbi.nlm.nih.gov/pubmed/25285531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0108694
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires